| Market Capitalization (Millions $) |
0 |
| Shares
Outstanding (Millions) |
30 |
| Employees |
- |
| Revenues (TTM) (Millions $) |
- |
| Net Income (TTM) (Millions $) |
-12 |
| Cash Flow (TTM) (Millions $) |
-18 |
| Capital Exp. (TTM) (Millions $) |
0 |
Business Description
Myrexis, Inc. was a biopharmaceutical company that focused on the discovery, development, and commercialization of drugs for the treatment of various diseases. It was headquartered in Salt Lake City, Utah, and operated as a subsidiary of a larger company called Myriad Genetics.
The company had a diverse pipeline of potential drug candidates, with a particular focus on oncology and autoimmune diseases. Myrexis aimed to leverage its expertise in drug discovery and development to bring innovative therapies to market and improve patient outcomes.
Unfortunately, in 2012, Myrexis made the decision to wind down its operations and exit the pharmaceutical industry. This decision was predominantly driven by challenges in securing funding and the company's strategic restructuring.
Overall, Myrexis, Inc. had the goal of developing new and effective treatments for various diseases, but ultimately discontinued its operations and shifted away from the biopharmaceutical sector.
|
